AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

STAR COMBO PHARMA LIMITED Capital/Financing Update 2018

Sep 11, 2018

65746_rns_2018-09-11_96936c59-2548-4f58-b535-2a25f7ccfa38.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

12 September 2018

==> picture [109 x 44] intentionally omitted <==

ASX Announcement - Growth Strategy in China

• Opening of Sales Office in Chongqing

• Products recently approved for sale in China

Star Combo Pharma Limited (ASX:S66) is pleased to announce the official opening of its first China representative office in Chongqing China. The manager in charge of the Chongqing office has more than 20 years of experience in the marketing of vitamins.

The Company has 7 products that were recently approved by Chinese authorities for offline sale in China.

These significant developments emphasise the Company’s overall growth strategy targeting the massive Chinese market. Establishing a physical presence in China will enable the Company to engage with its channel partners and customers more effectively and respond to consumer demand more efficiently. The Chinese market is expected to be a key contributor to the future revenue growth of the Company. .

For further information:

Su Zhang CEO Star Combo Pharma Limited E-mail: [email protected]